FDA Approves First Therapy for Recurrent Respiratory Papillomatosis

Published on: Precigen Investors

The U.S. FDA has granted full approval to PAPZIMEOS (zopapogene imadenovec-drba), the first therapy for adults with recurrent respiratory papillomatosis (RRP). This adenoviral vector-based immunotherapy targets HPV 6 and 11, addressing the root cause of the disease rather than just symptoms. Clinical trial data showed durable complete responses in over half of participants, many of whom avoided repeated surgeries for more than a year.

👉 Read the full article: Precigen Announces Full FDA Approval of PAPZIMEOS

Disclaimer:

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.